AstraZeneca Plc is to pay $50 million upfront to Amgen Inc in a deal where the two companies will jointly develop and commercialise five monoclonal antibodies from Amgen’s clinical inflammation portfolio. AZ announced the agreement on 2 April. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
